STRATIFYING RELAPSE RISK AFTER PRE-EMPTIVE RITUXIMAB IN IMMUNE- MEDIATED TTP: THE ROLE OF ADAMTS13 INHIBITOR TITER (SIE 2026) - Oct 6, 2026 - Abstract #DP050; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Eight pa- tients previously received caplacizumab (44%). Pre-emptive rituximab restored ADAMTS13 activity in most iTTP courses with limited toxici- ty, but relapses remained frequent. Lower baseline ADAMT- S13 inhibitor titer was associated with shorter biochemical and clinical DoR, possibly due to stronger association be- tween disease pathogenesis and higher inhibitor levels and improved outcomes using rituximab."
Hematological Disorders • Immunology • Infectious Disease • Thrombocytopenic Purpura • Urticaria
|
|
M. C. Limoli1; E. Longo1; U. Markovic1,2; S. Grasso1,2; F. Di Raimondo1; G. Giuffrida1,2
|